HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma

BACKGROUND: As a recognized highly immunogenic tumor, immune checkpoint blockades (ICB) have been widely used as a systemic treatment option for melanoma. However, only about half of treated patients could benefit from it in Caucasians, and only about 15% in Chinese melanoma patients. Robust predict...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Fu-xue, Wu, Jun-wan, Cheng, Xia-qin, Wang, Jiu-hong, Wen, Xi-zhi, Li, Jing-jing, Zhang, Qiong, Jiang, Hang, Ding, Qiu-yue, Zhu, Xiao-feng, Zhang, Xiao-shi, Ding, Ya, Li, Dan-dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395140/
https://www.ncbi.nlm.nih.gov/pubmed/36003385
http://dx.doi.org/10.3389/fimmu.2022.902167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395140/
https://www.ncbi.nlm.nih.gov/pubmed/36003385
http://dx.doi.org/10.3389/fimmu.2022.902167

Ejemplares similares